Maxipime: profile and news

Elan Shares Discounting $1.2B Tysabri Sales  Feb 1, 2006
...share. Elan attributed the earnings beat to better-than-expects sales of Maxipime and Azactam, along with lower research costs. ... - Forbes

Losses at Elan improve to $384m and shares rise  Jan 31, 2006
A breakdown of last year's sales showed they were boosted by strong growth for Maxipime and Azactam, while its new pain treatment, Prialt, recorded sales of ... - Irish Independent,

Europe: Telephone stocks fall as executives resign  Feb 1, 2006
55. Elan said its fourth-quarter loss narrowed, helped by its manufacturing business and injectable antibiotic Maxipime. Svenska ... - International Herald Tribune,

Elan meldt financiële resultaten vierde kwartaal en hele jaar ...  Jan 31, 2006
2005 US$m US$m US$m US$m ----- Revenue from Marketed Products 29.9 46.8 Maxipime(TM) 117.5 ... - Netherlands Corporate News (persbericht),

Elan Shares Discounting $1.2B Tysabri Sales  Feb 1, 2006
...share. Elan attributed the earnings beat to better-than-expects sales of Maxipime and Azactam, along with lower research costs. ... - Forbes

Loss Narrows for Elan  Jan 31, 2006
The increase of 28% was principally a result of higher sales of Maxipime and Azactam and revenue from Prialt, launched in 2005. ... - TheStreet.com

Losses at Elan improve to $384m and shares rise  Jan 31, 2006
A breakdown of last year's sales showed they were boosted by strong growth for Maxipime and Azactam, while its new pain treatment, Prialt, recorded sales of ... - Irish Independent,

UK Telephone Stocks Fall, Led by Cable & Wireless; Elan Gains  Jan 31, 2006
...its fourth-quarter loss narrowed to $58.3 million from $107.1 million a year earlier, helped by the manufacturing business and injectable antibiotic Maxipime. ... - Bloomberg

European Phone Stocks Drop, Led by Cable & Wireless; BASF Gains  Jan 31, 2006
...euros. Elan said its fourth-quarter loss narrowed, helped by the manufacturing business and injectable antibiotic Maxipime. Elan's ... - Bloomberg

Europe: Telephone stocks fall as executives resign  Feb 1, 2006
55. Elan said its fourth-quarter loss narrowed, helped by its manufacturing business and injectable antibiotic Maxipime. Svenska ... - International Herald Tribune,

Elan 'optimistic' on Tysabri return, earmarks cash for relaunch ...  Jan 31, 2006
Rising revenues from Elan's core products, including antibacterial drug Maxipime and antibiotic Azactam, and flat research and selling expenses have helped ... - Forbes

Elan cuts losses; earmarks funds for Tysabri return  Jan 31, 2006
...development activities and royalties added $59 million in the fourth quarter, a 45% increase year-on-year, while top product Maxipime (cefepime hydrochloride ... - Pharma Times (subscription),

CareNet Offering Information on Daiichi Pharmaceutical's Sunrhythm ...  Nov 25, 2005
...this month, the company provides information on Daiichi Pharmaceutical's anti-arrhythmic agent Sunrhythm and Bristol-Myers' cefepime antibiotic Maxipime. ... - TMCnet

Elan Reports Third Quarter 2005 Financial Results  Oct 26, 2005
...was $52.1 million in the thirdquarter of 2005, compared to $45.5 million recorded in the same periodof 2004 due to increased sales of Maxipime and Azactam, and ... - Finanzen.net,

Elan Reports Third Quarter 2005 Financial Results  Oct 27, 2005
...business, excluding Tysabri, continued to perform strongly with product revenues up over 40% over last year despite some disruption to the supply of Maxipime. ... - PharmaLive.com (press release),

Elan Reports Narrowed Loss  Oct 27, 2005
Elan had total product revenue for the third quarter of 2005 of $118.4 million, up 38% from a year ago on higher sales of its Maxipime and Azactam antibiotics ... - TheStreet.com

Elan cuts losses by 38pc in Q3  Oct 27, 2005
...safety concerns, continued to perform strongly with product revenues up over 40pc over last year to USD118.4m despite some disruption to the supply of Maxipime ... - Business World,

Elan pain drug sells below expectations  Oct 29, 2005
...m last year, is expected to come up against generic competition by the end of the year after its patent expired this month, while Maxipime, another antiobiotic ... - The Sunday Times,

Elan Reports Second Quarter 2005 Financial Results  Jul 27, 2005
The increase primarily reflects increased sales of Maxipime and Azactam. ... We will continue to closely monitor the supply level for Maxipime. ... - Business Wire (press release)

Elan shares plunge after death linked to top drug  Apr 1, 2005
...itself. The company has three other products, Maxipime, Prialt and Azactam, on the market and receives royalties on several others. ... - Express Newsline

Tysabri's woes weigh heaviest on Elan  Mar 31, 2005
...million. The company has three other products, Maxipime, Prialt and Azactam, on the market and receives royalties on several others. ... - MarketWatch

Firms hoped to expand sales for multiple sclerosis drugs  Mar 4, 2005
...million. The company has three other products, Maxipime, Prialt and Azactam, on the market and receives royalties on several others. ... - MarketWatch

Biogen/Elan's Tysabri adds pressure on FDA  Mar 6, 2005
...million. Elan has three other products, Maxipime, Prialt and Azactam, on the market and receives royalties on several others. In ... - FinFacts Ireland,

Drug/Laboratory Test Interactions: A false-positive reaction for glucose in the urine may occur with copper reduction tests (Benedictís or Fehlingís solution or with ClinitestÒ tablets) but not with enzyme-based tests for glycosuria. As a false-negative result may occur in the ferricyanide test, it is recommended that either the glucose oxidase or hexokinase method be used to determine blood plasma glucose levels in patients receiving cefuroxime.

Cefuroxime does not interfere with the assay of serum and urine creatinine by the alkaline picrate method.